Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033723 | 0.70 | OPRM1 (0.39) | DNM1FDPSOPRM1LAP3TSHR | |
| SCHEMBL5909004 | 0.69 | — | — | |
| SCHEMBL9011844 | 0.69 | — | — | |
| SCHEMBL5032052 | 0.69 | FDPS (0.39) | FDPSCA1CA2CYP3A4L3MBTL1 | |
| SCHEMBL30340675 | 0.68 | — | — | |
| Methoxymethane SCHEMBL2769299 | 0.67 | LMNA (0.43) | DNM1FDPSCA1CA2CYP3A4 | |
| SCHEMBL807201 | 0.67 | DNM1 (0.41) | DNM1FDPSCA1CA2CYP3A4 | |
| Iodide SCHEMBL5087653 | 0.66 | — | — | |
| Bromide SCHEMBL5087527 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL5091754 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176307-A1 | Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 | ARISAPH PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176307-A1 | Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 | DPP4, DPP7, DPP3 | DNM1 1841/4885FDPS 2477/4885CA1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.